WEE1 inhibition sensitizes osteosarcoma to radiotherapy

<p>Abstract</p> <p>Background</p> <p>The use of radiotherapy in osteosarcoma (OS) is controversial due to its radioresistance. OS patients currently treated with radiotherapy generally are inoperable, have painful skeletal metastases, refuse surgery or have undergone an...

Full description

Bibliographic Details
Main Authors: Helder Marco N, van Beusechem Victor W, Graat Harm CA, Würdinger Thomas, PosthumaDeBoer Jantine, van Royen Barend J, Kaspers Gertjan JL
Format: Article
Language:English
Published: BMC 2011-04-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/11/156
id doaj-3f7554069f434ddfa0bf80499aefff9d
record_format Article
spelling doaj-3f7554069f434ddfa0bf80499aefff9d2020-11-24T23:44:03ZengBMCBMC Cancer1471-24072011-04-0111115610.1186/1471-2407-11-156WEE1 inhibition sensitizes osteosarcoma to radiotherapyHelder Marco Nvan Beusechem Victor WGraat Harm CAWürdinger ThomasPosthumaDeBoer Jantinevan Royen Barend JKaspers Gertjan JL<p>Abstract</p> <p>Background</p> <p>The use of radiotherapy in osteosarcoma (OS) is controversial due to its radioresistance. OS patients currently treated with radiotherapy generally are inoperable, have painful skeletal metastases, refuse surgery or have undergone an intralesional resection of the primary tumor. After irradiation-induced DNA damage, OS cells sustain a prolonged G<sub>2 </sub>cell cycle checkpoint arrest allowing DNA repair and evasion of cell death. Inhibition of WEE1 kinase leads to abrogation of the G<sub>2 </sub>arrest and could sensitize OS cells to irradiation induced cell death.</p> <p>Methods</p> <p>WEE1 expression in OS was investigated by gene-expression data analysis and immunohistochemistry of tumor samples. WEE1 expression in OS cell lines and human osteoblasts was investigated by Western blot. The effect of WEE1 inhibition on the radiosensitivity of OS cells was assessed by cell viability and caspase activation analyses after combination treatment. The presence of DNA damage was visualized using immunofluorescence microscopy. Cell cycle effects were investigated by flow cytometry and WEE1 kinase regulation was analyzed by Western blot.</p> <p>Results</p> <p>WEE1 expression is found in the majority of tested OS tissue samples. Small molecule drug PD0166285 inhibits WEE1 kinase activity. In the presence of WEE1-inhibitor, irradiated cells fail to repair their damaged DNA, and show higher levels of caspase activation. The inhibition of WEE1 effectively abrogates the irradiation-induced G<sub>2 </sub>arrest in OS cells, forcing the cells into premature, catastrophic mitosis, thus enhancing cell death after irradiation treatment.</p> <p>Conclusion</p> <p>We show that PD0166285, a small molecule WEE1 kinase inhibitor, can abrogate the G<sub>2 </sub>checkpoint in OS cells, pushing them into mitotic catastrophe and thus sensitizing OS cells to irradiation-induced cell death. This suggests that WEE1 inhibition may be a promising strategy to enhance the radiotherapy effect in patients with OS.</p> http://www.biomedcentral.com/1471-2407/11/156
collection DOAJ
language English
format Article
sources DOAJ
author Helder Marco N
van Beusechem Victor W
Graat Harm CA
Würdinger Thomas
PosthumaDeBoer Jantine
van Royen Barend J
Kaspers Gertjan JL
spellingShingle Helder Marco N
van Beusechem Victor W
Graat Harm CA
Würdinger Thomas
PosthumaDeBoer Jantine
van Royen Barend J
Kaspers Gertjan JL
WEE1 inhibition sensitizes osteosarcoma to radiotherapy
BMC Cancer
author_facet Helder Marco N
van Beusechem Victor W
Graat Harm CA
Würdinger Thomas
PosthumaDeBoer Jantine
van Royen Barend J
Kaspers Gertjan JL
author_sort Helder Marco N
title WEE1 inhibition sensitizes osteosarcoma to radiotherapy
title_short WEE1 inhibition sensitizes osteosarcoma to radiotherapy
title_full WEE1 inhibition sensitizes osteosarcoma to radiotherapy
title_fullStr WEE1 inhibition sensitizes osteosarcoma to radiotherapy
title_full_unstemmed WEE1 inhibition sensitizes osteosarcoma to radiotherapy
title_sort wee1 inhibition sensitizes osteosarcoma to radiotherapy
publisher BMC
series BMC Cancer
issn 1471-2407
publishDate 2011-04-01
description <p>Abstract</p> <p>Background</p> <p>The use of radiotherapy in osteosarcoma (OS) is controversial due to its radioresistance. OS patients currently treated with radiotherapy generally are inoperable, have painful skeletal metastases, refuse surgery or have undergone an intralesional resection of the primary tumor. After irradiation-induced DNA damage, OS cells sustain a prolonged G<sub>2 </sub>cell cycle checkpoint arrest allowing DNA repair and evasion of cell death. Inhibition of WEE1 kinase leads to abrogation of the G<sub>2 </sub>arrest and could sensitize OS cells to irradiation induced cell death.</p> <p>Methods</p> <p>WEE1 expression in OS was investigated by gene-expression data analysis and immunohistochemistry of tumor samples. WEE1 expression in OS cell lines and human osteoblasts was investigated by Western blot. The effect of WEE1 inhibition on the radiosensitivity of OS cells was assessed by cell viability and caspase activation analyses after combination treatment. The presence of DNA damage was visualized using immunofluorescence microscopy. Cell cycle effects were investigated by flow cytometry and WEE1 kinase regulation was analyzed by Western blot.</p> <p>Results</p> <p>WEE1 expression is found in the majority of tested OS tissue samples. Small molecule drug PD0166285 inhibits WEE1 kinase activity. In the presence of WEE1-inhibitor, irradiated cells fail to repair their damaged DNA, and show higher levels of caspase activation. The inhibition of WEE1 effectively abrogates the irradiation-induced G<sub>2 </sub>arrest in OS cells, forcing the cells into premature, catastrophic mitosis, thus enhancing cell death after irradiation treatment.</p> <p>Conclusion</p> <p>We show that PD0166285, a small molecule WEE1 kinase inhibitor, can abrogate the G<sub>2 </sub>checkpoint in OS cells, pushing them into mitotic catastrophe and thus sensitizing OS cells to irradiation-induced cell death. This suggests that WEE1 inhibition may be a promising strategy to enhance the radiotherapy effect in patients with OS.</p>
url http://www.biomedcentral.com/1471-2407/11/156
work_keys_str_mv AT heldermarcon wee1inhibitionsensitizesosteosarcomatoradiotherapy
AT vanbeusechemvictorw wee1inhibitionsensitizesosteosarcomatoradiotherapy
AT graatharmca wee1inhibitionsensitizesosteosarcomatoradiotherapy
AT wurdingerthomas wee1inhibitionsensitizesosteosarcomatoradiotherapy
AT posthumadeboerjantine wee1inhibitionsensitizesosteosarcomatoradiotherapy
AT vanroyenbarendj wee1inhibitionsensitizesosteosarcomatoradiotherapy
AT kaspersgertjanjl wee1inhibitionsensitizesosteosarcomatoradiotherapy
_version_ 1725500262021332992